Navigation Links
Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Date:8/23/2007

SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will present updated results from its Phase 2 trial of picoplatin, including one-year survival data, during a poster discussion session at the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer in Seoul, Korea. Details follow:

Poster number: PD6-1-1

Title: A phase 2 study of picoplatin monotherapy for patients with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum-containing chemotherapy

Presenter: David A. Karlin, M.D., senior vice president, clinical development and regulatory affairs, at Poniard

Date: Monday, September 3, at 4:00 p.m. local time

Location: Room 310 of the Coex Convention Center

About Picoplatin

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the U.S. Food and Drug Administration (FDA) in November 2005 for picoplatin for the treatment of SCLC.

Poniard is currently evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Poniard is also evaluating intravenous pi
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Randomized Study Presented at ACOG 2009 Annual Meeting Confirming ... cohosh has been widely used in Europe and also ... flashes, night sweats, occasional irritability and mood swings. While ... question of liver safety has arisen in a few ...
... REDWOOD CITY, Calif., May 5 AcelRx Pharmaceuticals, ... Phase 2 clinical trial of its ARX-01 Sufentanil ... candidate being developed for management of acute post-operative ... objective of this open-label study is to assess ...
Cached Medicine Technology:No Causality Found Between Black Cohosh and Liver Problems 2AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 2AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 3
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
(Date:4/23/2014)... has long been considered to be between 180 and ... used refined microscopic techniques that indicate a much smaller ... tract is only as large as a normal studio ... which passes from the mouth through the esophagus and ... 5 meters in a normal adult, and is built ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Parents and physicians concerned about an increase in ... can breathe a sigh of relief. According to a ... years worth of data from states with and without ... to increased use among adolescents. The study is published ... of Adolescent Health . , "Any time a ...
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2
... one of the biggest controversies in fetal surgery and ... medicine physicians// around the world: What's the best way ... most common conditions requiring fetal surgery and the leading ... NIH-funded study on TTTS, conducted at 17 centers in ...
... a gift that brought tears to the receiver and to ... dollars was pledged to the staff at Toronto’s Hospital for Sick ... scion of a beer baron and well-established friend of the hospital. ... Management mutual fund company and his wife Sonia, have pledged this ...
... A child of seven years has succumbed to the flu, in British ... as it usually peaks in the months of December and January. ... say experts. ,According to Dr. Theresa Tam of the Public ... because of influenza and in a bad year that can go up ...
... fewer infection and death rates is announced by the NHS ... tried out successfully in United States. This announcement was received ... ,The incentive scheme initially is set for heart treatments, ... case of very sick patients and severe complications, the hospitals ...
... Cancer is a complex and common disease caused by ... ,Recent research shows that the constitutional mutation in PALB2 ... ,Previous studies have shown that genes are responsible ... of breast cancer. The two major familial breast cancer ...
... Using a unique weaving machine of their design, Duke ... "scaffold" that could greatly improve the ability of physicians ... cells. ,"If further experiments are successful, ... three or four years," said Franklin Moutos, a graduate ...
Cached Medicine News:Health News:Timeliness, a Critical Factor in Treating TTTS 2Health News:Timeliness, a Critical Factor in Treating TTTS 3Health News:Record Donation to Children’s Hospita 2Health News:Flu Strikes Late - Child Succumbs 2Health News:Mutation In PALB2 Elevates Risk of Cancer 2Health News:Woven Cartilage 2
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
...
Medicine Products: